Patents by Inventor Michael Dussiot

Michael Dussiot has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • BIOMARKER FOR USE IN TREATING ANEMIA
    Publication number: 20190049469
    Abstract: Provided herein are methods of treating diseases associated with anemia or ineffective erythropoiesis by using the level and/or activity of a ligand of an activin receptor, in particular, Growth differentiation factor 11 (GDF11), as an indicator of responsiveness of a patient to the treatment, efficacy of the treatment, or appropriate dosage for the treatment with an activin type II receptor inhibitor.
    Type: Application
    Filed: March 9, 2018
    Publication date: February 14, 2019
    Applicant: CELGENE CORPORATION
    Inventors: Victoria Sung, Rajesh Chopra, Olivier Hermine, Ivan Cruz Moura, Michael Dussiot, Thiago Trovati Maciel, Aurelie Fricot
  • Composition comprising a combination of DNA methylation inhibitor and a vitamin D receptor agonist for the treatment of drug resistant cancer or for the prevention of tumor relapse
    Patent number: 10111896
    Abstract: The present invention concerns a combination of (i) a DNA methylation inhibitor, and (ii) a Vitamin D receptor agonist, for simultaneous or sequential use in the treatment of a drug resistant cancer and/or in prevention of tumor relapse in a patient suffering from cancer. The present invention also relates to a combination of (i) a DNA methylation inhibitor, and (ii) a Vitamin D receptor agonist, for increasing, restoring or enhancing sensitivity of a patient suffering from cancer to a chemotherapeutic drug in a patient suffering from cancer.
    Type: Grant
    Filed: June 19, 2015
    Date of Patent: October 30, 2018
    Assignees: Institut National de la Sante et de la Recherche Medicale (INSERM), Centre National de la Recherche Scientifique (C.N.R.S.), Universite Paris Descartes, Foundation Imagine, Universite Paris Diderot—Paris 7, Universite Paris—Sud, Assistance Publique-Hopitaux de Paris (APHP)
    Inventors: Ivan Cruz-Moura, Olivier Hermine, Etienne Paubelle, Michael Dussiot, Thiago Trovati Maciel, Florence Zylbersztejn
  • METHODS FOR PREDICTING THE RESPONSIVENESS OF A PATIENT AFFECTED WITH MALIGNANT HEMATOLOGICAL DISEASE TO CHEMOTHERAPY TREATMENT AND METHODS OF TREATMENT OF SUCH DISEASE
    Publication number: 20180031579
    Abstract: The present invention relates to antagonists of GDF11, for use in the treatment of malignant hematological disease, such as Acute Myeloid Leukemia (AML). The present invention also relates to a method for predicting the responsiveness of a patient affected with malignant haematological disease, such as Acute Myeloid Leukemia, to a chemotherapy treatment.
    Type: Application
    Filed: February 11, 2016
    Publication date: February 1, 2018
    Inventors: Ivan CRUZ-MOURA, Valérie BARDET, Michaël DUSSIOT, Thiago TROVATI MACIEL, Jérôme TAMBURINI, Norbert IFRAH, Olivier HERMINE
  • Composition Comprising a Combination of DNA Methylation Inhibitor and a Vitamin D Receptor Agonist for the Treatment of Drug Resistant Cancer or for the Prevention of Tumor Relapse
    Publication number: 20170119804
    Abstract: The present invention concerns a combination of (i) a DNA methylation inhibitor, and (ii) a Vitamin D receptor agonist, for simultaneous or sequential use in the treatment of a drug resistant cancer and/or in prevention of tumor relapse in a patient suffering from cancer. The present invention also relates to a combination of (i) a DNA methylation inhibitor, and (ii) a Vitamin D receptor agonist, for increasing, restoring or enhancing sensitivity of a patient suffering from cancer to a chemotherapeutic drug in a patient suffering from cancer.
    Type: Application
    Filed: June 19, 2015
    Publication date: May 4, 2017
    Inventors: Ivan Cruz-Moura, Olivier Hermine, Etienne Paubelle, Michael Dussiot, Thiago Trovati Maciel, Florence Zylbersztejn
  • BIOMARKER FOR USE IN TREATING ANEMIA
    Publication number: 20150276766
    Abstract: Provided herein are methods of treating diseases associated with anemia or ineffective erythropoiesis by using the level and/or activity of a ligand of an activin receptor, in particular, Growth differentiation factor 11 (GDF11), as an indicator of responsiveness of a patient to the treatment, efficacy of the treatment, or appropriate dosage for the treatment with an activin type II receptor inhibitor.
    Type: Application
    Filed: October 23, 2013
    Publication date: October 1, 2015
    Applicant: CELGENE CORPORATION
    Inventors: Victoria Sung, Rajesh Chopra, Olivier Hermine, Ivan Cruz Moura, Michael Dussiot, Thiago Trovati Maciel, Aurelie Fricot
  • METHODS FOR TREATING ANEMIA
    Publication number: 20150266950
    Abstract: Provided herein are methods for the treatment of anemia, wherein the methods comprise administration of antagonists of Growth differentiation factor 11 (GDF1 1; also known as bone morphogenetic protein 11 (BMP11)) to a subject in need of the treatment.
    Type: Application
    Filed: October 23, 2013
    Publication date: September 24, 2015
    Applicant: CELGENE CORPORATION
    Inventors: Victoria Sung, Rajesh Chopra, Olivier Hermine, Ivan Cruz Moura, Michael Dussiot, Thiago Trovati Maciel, Aurelie Fricot
  • USE OF TRANSFERRIN RECEPTOR ANTAGONIST FOR THE TREATMENT OF THALASSEMIA
    Publication number: 20150197574
    Abstract: The present disclosure relates to antagonists of transferrin receptor and compositions and methods of use of said antagonists for treating pathological disorders such as thalassemia disorders
    Type: Application
    Filed: August 2, 2013
    Publication date: July 16, 2015
    Inventors: Ivan Cruz-Moura, Olivier Hermine, Michael Dussiot, Etienne Paubelle, Thiago Trovati Maciel